Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
25 results
D1.76 - Contact dermatitis in diabetic patients with wearable devices: A single-centre study
D1.87 - Kiwi allergy: A Comparative Analysis of Adult and Pediatric patients
D1.77 - Hereditary Angioedema in Real Life: Unmet Needs from the Patient Perspective
D1.78 - Non-Allergic Dermatologic Diagnoses Among Patients Presenting to an Allergy Immunology Outpatient Clinic: A Prospective Clinical Study
D1.79 - Heterogeneity of Non-Allergic Non-Eosinophilic Asthma: Clinical Subphenotypes and Allergy Belief Patterns
D1.82 - Pancake Syndrome: Molecular and Diagnostic Heterogeneity of Mite Sensitization
D1.83 - Cannabis-related severe anaphylaxis without cutaneous manifestations: atypical sensitization profile and mast cell disorder differential diagnosis in a case report
D1.84 - Invasion Meets Allergy: Cortaderia selloana as an Emerging Grass Aeroallergen
D1.85 - Baseline lung function and clinical outcomes in Allergic Bronchopulmonary Mycosis: A real-world cohort from a Severe Asthma Multidisciplinary Unit
D1.86 - Age-Related Features of Sensitization to Timothy Grass in Children According to Component-Resolved Diagnostics
D1.88 - An unusual diagnostic aid for Hymenoptera venom genuine versus cross sensitization: the field sting
D1.89 - Qualitative comparison between Euroline Respiratory Profile and Phadiatop for the screening of airborne allergies
D2.471 - Efficacy of omalizumab in the treatment of chronic spontaneous urticaria in children
D2.473 - Omalizumab as adjuvant therapy in drug desensitization to chemotherapy- a single Center experience
D2.475 - Treatment delay and likelihood of remission on omalizumab in chronic spontaneous urticaria: a real-world observational study
D2.464 - Stapokibart (anti–IL-4Rα monoclonal antibody) across type 2 inflammatory diseases in routine practice: a three-case series of severe atopic dermatitis, chronic urticaria with rhinosinusitis, and immune-related bullous pemphigoid
D2.465 - Omalizumab Enhances Safety and Supports Completion of Oral Immunotherapy in High-Risk Patients
D2.466 - More options for the treatment of Chronic Spontaneous Urticaria: Tezepelumab
D2.467 - Management of Netherton syndrome and hereditary angioedema with concurrent biologic therapy: a novel case
D2.468 - Real-world effectiveness and safety of dupilumab in pediatric atopic dermatitis: a retrospective cohort study
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download